Online inquiry

IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2750MR)

This product GTTS-WQ2750MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF11 gene. The antibody can be applied in Multiple myeloma (MM), Osteoporosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003701.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8600
UniProt ID O14788
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2750MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13600MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA R1450
GTTS-WQ2917MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ5571MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP-771
GTTS-WQ11126MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ3823MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BB-10901
GTTS-WQ9308MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ12959MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ1813MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW